» Articles » PMID: 33833938

Latin-American Registry of Cardiovascular Disease and COVID-19: Rationale and Design of the CARDIO COVID 19-20 Registry

Abstract

Background: Infection caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) exhibits a strong infectivity but less virulence compared to severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). In terms of cardiovascular morbidity, susceptible population include elderly and patients with certain cardiovascular conditions. This infection has been associated with cardiac injury, cardiovascular complications and higher mortality.

Objectives: The main objective of the CARDIO COVID 19-20 Registry is to determine the presence of cardiovascular comorbidities and cardiovascular complications in COVID-19 infected patients that required in-hospital treatment in different Latin American institutions.

Methods: The CARDIO COVID 19-20 Registry is an observational, multicenter, ambispective, and hospital-based registry of patients with confirmed COVID-19 infection who required in-hospital treatment in Latin America. Enrollment of patients started on May 01, 2020 and was initially planned to last three months; based on the progression of pandemic in Latin America, enrollment was extended until December 2020, and could be extended once again based on the pandemic course in our continent at that moment.

Conclusions: The CARDIO COVID 19-20 Registry will characterize the in-hospital population diagnosed with COVID-19 in Latin America in order to identify risk factors for worsening of cardiovascular comorbidities or for the appearance of cardiovascular complications during hospitalization and during the 30-day follow up period.

Citing Articles

Biochemical differences based on sex and clusters of biomarkers in patients with COVID-19: analysis from the CARDIO COVID 19-20 registry.

Canon-Estrada F, Munoz-Ordonez J, Escalante-Forero M, Rodas Y, Arteaga-Tobar A, Azcarate-Rodriguez V BMC Cardiovasc Disord. 2025; 25(1):147.

PMID: 40045210 PMC: 11881352. DOI: 10.1186/s12872-025-04565-3.


Impact of myocardial injury on cardiovascular complications in hospitalized patients with COVID-19: insights from Latin America.

Cardenas-Marin P, Cordoba-Melo B, Carrillo-Gomez D, Leon-Giraldo H, Mendoza I, Florez N Front Cardiovasc Med. 2025; 12:1545142.

PMID: 40034989 PMC: 11872895. DOI: 10.3389/fcvm.2025.1545142.


Marked Global Differences in Mortality in Male Patients with COVID-19: An Analysis of the CARDIO COVID 19-20 and WHF COVID-19 CVD Studies.

Gomez-Mesa J, Arango-Ibanez J, Perel P, Prabhakaran D, Leon-Giraldo H, Toro-Pedroza A Glob Heart. 2025; 20(1):21.

PMID: 40026348 PMC: 11869830. DOI: 10.5334/gh.1403.


Cardiovascular Outcomes in Hospitalized Patients with COVID-19: Does Age Really Matter?.

Sotomayor-Julio A, Escalante M, Rodas-Cortes Y, Arteaga-Tobar A, Valencia A, Wyss F J Cardiovasc Dev Dis. 2025; 12(2).

PMID: 39997475 PMC: 11856037. DOI: 10.3390/jcdd12020041.


Long COVID Clusters of Symptoms Persist beyond Two Years after Infection: Insights from the CARDIO COVID 20-21 Registry.

Arango-Ibanez J, Cordoba-Melo B, Gutierrez Posso J, Barbosa-Rengifo M, Herrera C, Quintana Da Silva M Viruses. 2024; 16(7).

PMID: 39066191 PMC: 11281355. DOI: 10.3390/v16071028.


References
1.
Xiong T, Redwood S, Prendergast B, Chen M . Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020; 41(19):1798-1800. PMC: 7454513. DOI: 10.1093/eurheartj/ehaa231. View

2.
Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

3.
Lopes R, Macedo A, de Barros E Silva P, Moll-Bernardes R, Feldman A, Arruda G . Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. Am Heart J. 2020; 226:49-59. PMC: 7219415. DOI: 10.1016/j.ahj.2020.05.002. View

4.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

5.
Driggin E, Madhavan M, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G . Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020; 75(18):2352-2371. PMC: 7198856. DOI: 10.1016/j.jacc.2020.03.031. View